C12N 15/73
Expression systems using phage regulatory sequences
Official title: Expression systems using phage (lambda) regulatory sequences
C12N15/73 (Expression systems using phage regulatory sequences) appears on 168 US grants and 94 published applications in this corpus.
Search patents in C12N- Granted patents
- 168
- Published applications
- 94
- Assignees
- 98
- Inventors
- 370
- Latest grant
- 28 Jan 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 7 | 0 |
| 1990 | 4 | 0 |
| 1991 | 5 | 0 |
| 1992 | 12 | 0 |
| 1993 | 7 | 0 |
| 1994 | 0 | 0 |
| 1995 | 10 | 0 |
| 1996 | 4 | 0 |
| 1997 | 14 | 0 |
| 1998 | 6 | 0 |
| 1999 | 4 | 0 |
| 2000 | 8 | 0 |
| 2001 | 9 | 1 |
| 2002 | 4 | 2 |
| 2003 | 3 | 1 |
| 2004 | 3 | 2 |
| 2005 | 3 | 7 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 3 | 4 |
| 2010 | 5 | 8 |
| 2011 | 1 | 2 |
| 2012 | 1 | 1 |
| 2013 | 3 | 4 |
| 2014 | 2 | 4 |
| 2015 | 4 | 4 |
| 2016 | 6 | 4 |
| 2017 | 4 | 5 |
| 2018 | 3 | 1 |
| 2019 | 1 | 12 |
| 2020 | 2 | 8 |
| 2021 | 8 | 7 |
| 2022 | 4 | 4 |
| 2023 | 2 | 2 |
| 2024 | 7 | 5 |
| 2025 | 1 | 3 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction28 Jan 2025US 12,209,256 B2The Trustees of Princeton University
- Composition for editing a nucleic acid sequence and method using the same12 Nov 2024US 12,139,716 B2
- T cell activating bispecific antigen binding molecules1 Oct 2024US 12,103,982 B2Hoffmann-La Roche Inc.
- Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof9 Apr 2024US 11,952,594 B2Eligo Bioscience
- Methods and systems for detection of antibiotic resistance9 Apr 2024US 11,952,611 B2Laboratory Corporation of America Holdings
- Cell-free expression vectors and methods for improved protein production13 Aug 2026US 2026/0234646 A1National Resilience, Inc.
- Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof13 Nov 2025US 2025/0345378 A1Locus Biosciences, Inc.
- Continuous Multiplexed Phage Genome Engineering Using a Retron Editing Template17 Jul 2025US 2025/0230429 A1The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
- Probiotic vaccines and related methods of use8 May 2025US 2025/0144193 A1Salvitus, Inc.
- Methods and Systems for Detection of Antibiotic Resistance5 Dec 2024US 2024/0401105 A1
Most cited
By later US patents
- Methods for producing members of specific binding pairs893US 5,969,108 ACambridge Antibody Technology Limited · 1999
- Generation and selection of novel DNA-binding proteins and polypeptides293US 5,096,815 AProtein Engineering Corporation · 1992
- Cloning and expression of the gene for bacteriophage T7 RNA polymerase285US 4,952,496 AAssociated Universities, Inc. · 1990
- Generation and selection of novel DNA-binding proteins and polypeptides254US 5,198,346 AProtein Engineering Corporation · 1993
- Methods for producing members of specific binding pairs240US 5,871,907 ACambridge Antibody Technology Limited · 1999